MYGN

Myriad Genetics (MYGN)

Myriad Genetics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:MYGN

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/09/24	05:21	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/09/24	05:17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/09/24	05:15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/09/18	21:00	GlobeNewswire Inc.	Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference	NASDAQ:MYGN	Myriad Genetics Inc
2024/09/17	03:30	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/09/13	05:11	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/09/13	05:09	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/09/12	04:26	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/09/11	23:05	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/09/10	06:48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/09/10	03:52	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/09/05	21:00	GlobeNewswire Inc.	Myriad Genetics to Host Investor Event on October 9, 2024	NASDAQ:MYGN	Myriad Genetics Inc
2024/09/05	08:51	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/09/05	08:38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/09/04	05:33	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/09/03	23:11	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/08/27	05:48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/08/24	05:16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/08/21	05:38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/08/20	03:46	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/08/15	05:27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/08/07	21:22	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MYGN	Myriad Genetics Inc
2024/08/07	05:09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MYGN	Myriad Genetics Inc
2024/08/07	05:05	GlobeNewswire Inc.	Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%	NASDAQ:MYGN	Myriad Genetics Inc
2024/08/02	05:05	GlobeNewswire Inc.	Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific	NASDAQ:MYGN	Myriad Genetics Inc
2024/07/31	21:50	GlobeNewswire Inc.	Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer	NASDAQ:MYGN	Myriad Genetics Inc
2024/07/30	21:00	GlobeNewswire Inc.	Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024	NASDAQ:MYGN	Myriad Genetics Inc
2024/07/17	21:00	GlobeNewswire Inc.	What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk	NASDAQ:MYGN	Myriad Genetics Inc
2024/07/11	22:00	GlobeNewswire Inc.	Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing	NASDAQ:MYGN	Myriad Genetics Inc
2024/07/09	22:00	GlobeNewswire Inc.	Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date	NASDAQ:MYGN	Myriad Genetics Inc